Details

Autor(en) / Beteiligte

• Balaz, David
• Wikman-Jorgensen, Philip Erick
• Galvañ, Vicente Giner
• Rubio-Rivas, Manuel
• de Miguel Campo, Borja
• López, Mariam Noureddine
• Caleya, Juan Francisco López
• Huelgas, Ricardo Gómez
• Fontán, Paula María Pesqueira
• Bailón, Manuel Méndez
• Fernández-Garcés, Mar
• Cruz, Ana Fernández
• García, Gema María García
• Rhyman, Nicolás
• Corral-Gudino, Luis
• Rodríguez-Mancheño, Aquiles Lozano
• De La Chica, María Navarro
• García, Andrea Torregrosa
• Alcalá, José Nicolás
• Jiménez, Pablo Díaz
• Trallero, Leticia Esther Royo
• Casanova, Pere Comas
• Núñez-Cortés, Jesús Millán
• Casas-Rojo, José-Manuel
• On Behalf Of The Semi-Covid-Network

Titel

Evolution of the Use of Corticosteroids for the Treatment of Hospitalised COVID-19 Patients in Spain between March and November 2020: SEMI-COVID National Registry

Ist Teil von

• Journal of clinical medicine, 2021-10, Vol.10 (19), p.4610

Ort / Verlag

Switzerland: MDPI AG

Erscheinungsjahr

2021

Quelle

Free E-Journal (出版社公開部分のみ）

Beschreibungen/Notizen

• Since the results of the RECOVERY trial, WHO recommendations about the use of corticosteroids (CTs) in COVID-19 have changed. The aim of the study is to analyse the evolutive use of CTs in Spain during the pandemic to assess the potential influence of new recommendations. A retrospective, descriptive, and observational study was conducted on adults hospitalised due to COVID-19 in Spain who were included in the SEMI-COVID-19 Registry from March to November 2020. CTs were used in 6053 (36.21%) of the included patients. The patients were older (mean (SD)) (69.6 (14.6) vs. 66.0 (16.8) years; < 0.001), with hypertension (57.0% vs. 47.7%; < 0.001), obesity (26.4% vs. 19.3%; < 0.0001), and multimorbidity prevalence (20.6% vs. 16.1%; < 0.001). These patients had higher values (mean (95% CI)) of C-reactive protein (CRP) (86 (32.7-160) vs. 49.3 (16-109) mg/dL; < 0.001), ferritin (791 (393-1534) vs. 470 (236-996) µg/dL; < 0.001), D dimer (750 (430-1400) vs. 617 (345-1180) µg/dL; < 0.001), and lower Sp0 /Fi0 (266 (91.1) vs. 301 (101); < 0.001). Since June 2020, there was an increment in the use of CTs (March vs. September; < 0.001). Overall, 20% did not receive steroids, and 40% received less than 200 mg accumulated prednisone equivalent dose (APED). Severe patients are treated with higher doses. The mortality benefit was observed in patients with oxygen saturation </=90%. Patients with greater comorbidity, severity, and inflammatory markers were those treated with CTs. In severe patients, there is a trend towards the use of higher doses. The mortality benefit was observed in patients with oxygen saturation </=90%.